Xvivo Perfusion AB 

$29.39
6
+$0.00+0% Friday 13:30

統計

當日最高
29.39
當日最低
29.39
52週高點
33.45
52週低點
16.98
成交量
-
平均成交量
-
市值
0
本益比
76.6
股息殖利率
-
股息
-

即將到來

財報

14Jul預期
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
下一步
-0.04
0.02
0.07
0.12
預期EPS
0.086901
實際EPS
不適用

財務

2.05%利潤率
有盈利
2020
2021
2022
2023
2024
2025
236.82M營收
4.85M淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 XVIPF 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Xvivo Perfusion AB (publ) is a medical technology company dedicated to advancing transplantation medicine. The firm specializes in pioneering solutions for the preservation and perfusion of organs, tissues, and cells, essential for successful transplant procedures. With a significant international presence, Xvivo Perfusion operates across diverse markets, including Sweden, the United States, wider North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Among its key product offerings is the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass apparatus designed for normothermic ex vivo lung perfusion (EVLP). Complementing this, the company provides the XPS Disposable Lung Kit, comprising sterile, pre-packaged components required for EVLP, and STEEN Solution, a specialized buffered extracellular fluid used for perfusing isolated donor lungs during the EVLP process. Xvivo also offers Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte solution crucial for preservation. Other significant products include the XVIVO Silicone Tubing Set for rapid flushing of donor lungs post-procurement; the XVIVO LS and XVIVO Disposable Lung Set, devices engineered for EVLP; and the XVIVO Organ Chamber, a single-use sterile container designed for the temporary storage of isolated lungs prior to their transplantation into a recipient. Additionally, the XVIVO Lung Cannula Set, a sterile, single-use disposable product, is part of their portfolio. Established in 1998, Xvivo Perfusion AB (publ) maintains its headquarters in Gothenburg, Sweden.
Show more...
執行長
Mr. Christoffer Rosenblad
員工
193
國家
瑞典
ISIN
SE0004840718

上市

0 Comments

分享你的想法

FAQ

Xvivo Perfusion AB 今天的股價是多少?
XVIPF 目前價格為 $29.39 USD,過去 24 小時上漲了 +0%。在圖表上更密切關注 Xvivo Perfusion AB 股價表現。
Xvivo Perfusion AB 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Xvivo Perfusion AB 的股票以代號 XVIPF 進行交易。
Xvivo Perfusion AB 下一次財報日期是什麼時候?
Xvivo Perfusion AB 將於 July 14, 2026 公布下一次財報。
Xvivo Perfusion AB 上一季度的財報如何?
XVIPF 上一季度的財報為每股 0.12 USD,預估為 0.1 USD,帶來 +24.49% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Xvivo Perfusion AB 去年的營收是多少?
Xvivo Perfusion AB 去年的營收為 236.82MUSD。
Xvivo Perfusion AB 去年的淨利是多少?
XVIPF 去年的淨收益為 4.85MUSD。
Xvivo Perfusion AB 有多少名員工?
截至 June 12, 2026,公司共有 193 名員工。
Xvivo Perfusion AB 位於哪個產業?
Xvivo Perfusion AB從事於Health & Wellness產業。
Xvivo Perfusion AB 何時完成拆股?
Xvivo Perfusion AB 最近沒有進行任何拆股。
Xvivo Perfusion AB 的總部在哪裡?
Xvivo Perfusion AB 的總部位於 瑞典 的 Mölndal。